Taiwan's Health2Sync has announced that its latest version of the Health2Sync App integrates insulin data from Mallya Cap, the connected device dedicated to insulin pens developed by Biocorp and marketed in Japan by Novo Nordisk.

This partnership realises the first data integration of its kind in the world and is expected to help patients on insulin treatment manage their health by capturing multiple data points, including insulin injection logs.

The population of diabetes and pre-diabetes exceeds 20 million in Japan. Owing to the advances in insulin and non-insulin drugs during the past two decades, the combined use of those drugs in Japan increased, and the glycemic control leveled off after 2014 in patients with type 2 diabetes. However, according to a 2017 study, 44% of Japanese diabetes patients still reported omission or non-adherence to insulin, a greater value than that reported in other countries. 

Mallya is a non-medical smart sensor that attaches directly to the FlexTouch insulin pen, saving time and effort from manually inputting or recording injection data. After attaching the Mallya cap to a FlexTouch pen, the smart cap enables automatic data collection and sends the injection dosage, date, and time to the Health2Sync App wirelessly in real-time.

The synchronised data can be analysed with diet and blood glucose levels by the Health2Sync App, providing further analyses and a more accurate understanding of personal glucose management and lifestyle adjustments.

The Mallya data integration is now available to the 350,000 Health2Sync users in Japan. Health2Sync plans to deploy comprehensive digital insulin management experiences to other countries this year.